181 results about "Interleukin receptor" patented technology

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The disclosure provides interleukin 21 (IL-21) variants that have (i) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide; or (ii) increased stability as compared to a wild-type human IL-21 polypeptide; or (iii) decreased or no binding to a human interleukin 21 receptor (IL-21R) as compared to a wild-type human IL-21 polypeptide and increased stability as compared to a wild-type human IL-21 polypeptide. The disclosure also provides fusion proteins including an antibody or fragment thereof bound, e.g., covalently linked, to an IL-21 variant.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

A nanoparticle for delivering an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor to a subject and methods for treating inflamed tissue in a subject using the nanoparticle.

The present invention provides methods for treating atopic dermatitis (AD). Also provided are methods for improving one or more AD-associated parameter(s), and methods for decreasing the level of at least one AD-associated biomarker in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody.

The present disclosure provides an anti-IL13RA2 single domain antibody (e.g., a VHH domain antibody), and a chimeric antigen receptor (CAR) that binds IL13RA2, the chimeric antigen receptor comprising: the anti-IL13RA2 single domain antibody in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune effector cells transduced with the disclosed CAR constructs can be used in cancer immunotherapy.

This document provides methods and materials involved in treating cancer. For example, methods and materials for modulating (e.g., increasing or decreasing) an interleukin-1 (IL-1) signaling pathway (e.g., an IL-1βsignaling pathway) during an adoptive cell therapy (e.g., a chimeric antigen receptor (CAR) T cell therapy) are provided. In some cases, one or more inhibitors of an interleukin-1 receptor antagonist (IL-1RA) polypeptide can be used to increasing IL-1 signaling (e.g., to reduce immunosuppression of the administered cells). In some cases, CAR T cells having a reduced level of an interleukin 1 receptor, type I (IL-1R1) polypeptide can have decreased IL-1 signaling (e.g., to reduce T cell toxicity associated with the administered cells).

Natural killer cells engineered to express a chimeric antigen receptor (CAR) having a Toll / interleukin-1 (IL-1) receptor (TIR) signaling domain, such as a Toll-like receptor (TLR) signaling domain or an IL-1 receptor (IL-1 R) subfamily signaling domain, are provided. Compositions and methods for making and using the natural killer cells in immunotherapy for cancer are also provided. And the CAR-NK cell can be a CISH <-> / -iPSC-NK cell.

Provided are compositions and methods for a cell population comprising engineered cytotoxic innate lymphoid cells engineered for controlled expansion and / or activity, the engineered cytotoxic innate lymphoid cells comprising a synthetic cytokine receptor for a non-physiological ligand. The cytokine receptor may comprise a synthetic gamma chain polypeptide as a first dimerization domain, a first transmembrane domain, and an interleukin-2 receptor subunit gamma (IL-2RG) intracellular domain and a synthetic beta chain polypeptide as a second dimerization domain, a second transmembrane domain, and an intracellular domain selected from an interleukin-2 receptor subunit beta (IL-2RB) intracellular domain, an interleukin-7 receptor subunit beta (IL-7RB) intracellular domain, and / or an interleukin-21 receptor subunit beta (IL-21RB) intracellular domain. The non-physiological ligand activates the synthetic cytokine receptor in the cytotoxic innate lymphoid cells to induce expansion and / or activation of the engineered cytotoxic innate lymphoid cells.

The invention discloses an antibody or an antigen binding fragment capable of specifically recognizing and / or binding an anti-interleukin 6 receptor. Belongs to the field of antibody engineering. The antibody or the antigen binding fragment provided by the invention has higher biological activity, FcRn affinity and stronger antibody stability, and has a good clinical application prospect.

Provided are antibodies and antigen binding fragments thereof that bind to human interleukin-11 receptor subunit α (IL-11Rα) and related compositions, which may be used in any of a variety of therapeutic or diagnostic methods, including the treatment or diagnosis of cancers, inflammatory diseases, autoimmune diseases, and others.

Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula IAlso disclosed are methods of making and using the compounds and compositions. The disclosed compounds and / or compositions may be used to treat or prevent an IRAK-associated disease or condition.

The present invention relates to multispecific antigen binding proteins that comprise an antigen-binding regions specific for a tumor-associated antigen (TAA), an antigen-binding region that specifically binds an epitope of a γδ T cell receptor (TCR), a γδ T cell-activating cytokine, and optionally, a γδ T cell co-stimulatory agonist. The γδ T cell-activating cytokine preferably is at least 5 one of an interleukin 21 receptor (IL21R) agonist and an interleukin 15 receptor (IL15R) agonist. The γδ T cell co-stimulatory agonist cytokine preferably is at least one of a 4-1BB agonist, a CD27 agonist and a GITR agonist. The multispecific antigen binding proteins of the invention specifically redirect and activate γδ T cell to lyse targeted tumor cells. The invention further relates to the use of such multispecific antigen binding proteins in the treatment of cancer, preferably a cancer 10 expressing the TAA.

The invention provides a human interleukin 5 alpha receptor IL5RA mRNA (messenger Ribonucleic Acid) detection primer probe group, a kit and application, and belongs to the technical field of biological detection. A detection primer probe group is limited to comprise IL5RA-F, IL5RA-R and a probe I5-Probe, the expression level of human interleukin 5 alpha receptor (IL5RA) mRNA is detected in cooperation with an RNA one-step method, the content change of IL5RA can be sensitively detected, and compared with an immunological detection method, the detection sensitivity can be greatly improved, a low-concentration clinical sample can be detected, and the detection method has the advantages that the detection time is shortened, and the detection cost is reduced. The detection range can span at least five orders of magnitude, the accuracy of the detection result is improved, and at least 80 persons can be detected within one hour, so that the treatment effect can be dynamically monitored and evaluated more accurately and quickly in an earlier stage.

The present application relates to a novel antibody or antibody fragment thereof of interleukin-23 receptor, which can effectively bind IL-23R, block the binding of IL-23R and human IL-23 alpha / IL-12 beta heterodimer ligand, and has good application prospect. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises VH CDR1, VH CDR2 and VH CDR3, and the light chain variable region comprises VL CDR1, VL CDR2 and VL CDR3, wherein VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 3, 13 or 23, VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 4, 14 or 24, VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 5, 15 or 25; VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 8, 18 or 28, VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 9, 19 or 29, and VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 10, 20 or 30.

This invention relates to antibody-drug conjugates and their uses. An antibody-drug conjugate having a structure represented by formula (I) is provided: Ab-(L-D) n (I), wherein Ab is an antibody against the interleukin-6 receptor or an antigen-binding fragment thereof, said antibody or antigen-binding fragment comprising at least one light chain and at least one heavy chain as described herein, and the use of the antibody-drug conjugate. The antibody-drug conjugate of the present invention can significantly reduce the dosage, improve patient tolerability, and reduce adverse reactions.

The present invention provides for chimeric antigen receptor constructs capable of being expressed in dendritic cells (DCs), and DCs modified to express one or more chimeric antigen receptors (CARs) as well as compositions comprising these modified DCs and methods of stimulating an adaptive immune response in a subject. The intracellular domain of the CAR comprises a toll-interleukin receptor (TIL) intracellular signalling domain and a costimulating domain selected from CD3 signalling domain, CD28 signalling domain and a combined CD28 and CD3 signalling domain.

The present invention relates to a peptide inhibitor of an interleukin-23 receptor and a use thereof. In particular, the present invention relates to peptide inhibitors of the interleukin-23 receptor, stereoisomers or pharmaceutically acceptable salts or solvates thereof, pharmaceutical compositions thereof, and uses of the peptide inhibitors in the treatment or prevention of diseases or conditions including inflammatory bowel disease, Crohn's disease and psoriasis.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

Described herein are interleukin-10 receptor-2 peptides, antibodies that bind the peptides, compositions including the peptides and antibodies and methods of use of the peptides and antibodies. The interleukin-10 receptor-2 peptide consists of an 8-15 amino acid sequence that includesSEQ ID NO: 1((I / V)P(P / K / V / E)P(E / K / R / Q)N(A / V)R), SEQ ID NO: 2((S / L / V)PAF(A / P)(K / Q)(G / T / E)(N / T / D)), or SEQ ID NO: 3(PP(G / T / Q / V)(V / T / A)(R / H / T / S)(GN / NHP / SAA)).

The present invention relates to a peptide inhibitor of interleukin-23 receptor, and a use thereof. In particular, it relates to a peptide inhibitor of interleukin-23 receptor, a stereoisomer, pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition thereof, and a use of the peptide inhibitor in treating or preventing diseases or conditions comprising inflammatory bowel disease, Crohn's disease, and psoriasis.

The present invention relates to a process for preparing a crystalline form of a monocyclic peptide compound, which is a peptide inhibitor of the interleukin-23 receptor (IL-23R), or a salt or solvate thereof. The crystalline forms are pharmaceutical compositions, methods and / or uses for the treatment of autoimmune inflammatory diseases and related conditions.

The present invention relates to novel cyclic peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, methods and / or uses for treatment of autoimmune inflammation and related diseases and disorders.

The present invention relates to an antisense oligonucleotide targeting an interleukin 4 receptor and the use thereof. The antisense oligonucleotide (ASO) molecule has a length of 16-22 bases and is specifically paired with a specific region of a target gene (interleukin 4 receptor). The ASO is used for treating diseases associated with IL-4Rα, which includes, but is not limited to, asthma (including eosinophilic asthma), atopic dermatitis, eosinophilic esophagitis, sinusitis, nasal polyps, prurigo nodularis, urticaria, chronic obstructive pulmonary disease, bullous pemphigoid, pruritus, and gastritis.

Modified natural killer (NK) or T cells expressing hematopoietic growth factor receptors are provided. In some aspects, the modified NK cells or T cells express a thrombopoietin receptor, an erythropoietin receptor, or a chimeric polypeptide including an extracellular domain of a thrombopoietin receptor, a transmembrane domain, and an intracellular domain including an interleukin receptor intracellular signaling domain. Methods of treating a subject with cancer are also provided, including administering the modified NK cells or T cells to the subject in combination with a thrombopoietin receptor agonist or erythropoietin receptor agonist, and in some example, interleukin-2, particularly reduced or low-dose amounts of IL-2.

The present disclosure relates generally to compositions and methods for modulating signal transduction mediated by interleukin-10 (IL10). In particular, the disclosure provides IL10 polypeptide variants with altered binding affinity to interleukin-10 receptor subunit beta (IL10Rbβ). Also provided are compositions and methods useful for producing such IL10 polypeptide variants, as well as methods for modulating IL10-mediated signaling, and / or for the treatment of conditions associated with the perturbation of signal transduction mediated by IL10.

Provided are antibodies and fragments against human interleukin-4 receptor alpha (hIL-4Rα) and uses thereof. The antibodies and fragments preferably have heavy chain complementary determining regions as set forth in SEQ ID NOs: 1-3 or 14-16 and light chain complementary determining regions as set forth in SEQ ID NOs: 4-6 or 17-19.

Methods for treating bullous pemphigoid in a subject are provided. In one aspect, the methods comprise administering to a subject having bullous pemphigoid one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

Methods for treating moderate to severe atopic dermatitis in hands and / or feet in a subject are provided. In one aspect, the method comprises administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or an antigen-binding fragment thereof.

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and / or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.